XML 54 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration and License Agreements - Additional Information (Details) - USD ($)
6 Months Ended
Sep. 10, 2018
Feb. 24, 2016
Jun. 30, 2019
Jun. 30, 2018
Jan. 01, 2019
Dec. 31, 2018
Collaboration and License Agreements [Line items]            
Deferred revenue     $ 7,129,000   $ 8,029,000 $ 8,436,000
Development and Commercial License Agreement | Servier            
Collaboration and License Agreements [Line items]            
Upfront payment   $ 105,000,000        
Recognized revenue under agreement     3,000,000 $ 2,900,000    
Deferred revenue     85,200,000     88,600,000
Development or sales-based milestone payments     0 $ 0    
Development and Commercial License Agreement | Servier | Current Liabilities            
Collaboration and License Agreements [Line items]            
Deferred revenue     5,900,000     6,400,000
Development and Commercial License Agreement | Servier | Maximum            
Collaboration and License Agreements [Line items]            
Total payments to be received   1,600,000,000        
Aggregate milestone payments   1,500,000,000        
Development milestone payments   401,300,000        
Commercial milestone payments   $ 1,100,000,000        
Collaboration and License Agreement | Gilead            
Collaboration and License Agreements [Line items]            
Recognized revenue under agreement     6,700,000      
Deferred revenue     1,200,000     2,300,000
Development or sales-based milestone payments     $ 0      
Research funding payment term 3 years   3 years      
Semi-annual research funding payments $ 40,000,000          
Collaboration and License Agreement | Gilead | Current Liabilities            
Collaboration and License Agreements [Line items]            
Deferred revenue     $ 1,200,000     $ 2,300,000
Collaboration and License Agreement | Gilead | Maximum            
Collaboration and License Agreements [Line items]            
Development milestone payments 105,000,000          
Commercial milestone payments 340,000,000          
Receivable from research funding 40,000,000          
Development and commercial milestone payments $ 445,000,000